Table 2.
Patient characteristics (N _54)*
| Characteristics | No. of patients | % |
|---|---|---|
| Age, years | ||
| <65 | 27 | 50 |
| ≥65 | 27 | 50 |
| Sex | ||
| Male | 30 | 55.6 |
| Female | 24 | 44.4 |
| Primary tumour site | ||
| Intrahepatic bile duct | 20 | 37 |
| Gallbladder | 18 | 33.3 |
| Extrahepatic bile duct | 13 | 24.1 |
| Ampulla of vater | 3 | 5.6 |
| Extent of disease | ||
| Metastatic | 34 | 63 |
| Locally advaced | 20 | 37 |
| Resection | ||
| No | 37 | 68.5 |
| Yes | 17 | 31.5 |
| Lymphocyte | ||
| ≥18 % | 45 | 83.3 |
| <18 % | 9 | 16.7 |
| PS (ECOG) | ||
| 0 | 49 | 90.7 |
| 1 | 5 | 9.3 |
Clinical characteristics of the 54 patients who received elpamotide+GEM
PS (ECOG) Performance status (Eastern Cooperative Oncology Group)